Soteria Precision Medicine Foundation Partners with Translational Genomics Research Institute (TGen) to Inform Cancer Care for Special Operations Forces
Effort will provide leading-edge precision medicine navigation for Special Operation Forces in their battle against cancer through comprehensive genomic testing and analysis conducted by TGen
PHOENIX, AZ (Oct. 23, 2024) — Soteria Precision Medicine Foundation, a non-profit organization dedicated to providing leading-edge patient precision medicine navigation services to individuals with cancer diagnoses, today announced a partnership with the Translational Genomics Research Institute (TGen), part of City of Hope, to provide precision medicine navigation for Special Operation Forces in their battle against cancer.
Through the strategic agreement with TGen, Soteria will deploy, and scale precision medicine navigation capabilities tailored to meet the unique needs of Special Operation Forces (SOF) members confronting cancer. Soteria is working with multiple SOF non-profit support organizations to enhance awareness and provide access to this program. Through this partnership, Soteria will address the most significant identified gaps in cancer care for this military community.
In collaboration with TGen, Soteria will enable patients, their families and care teams to access leading edge, multi-omic diagnostic tests and data analytics. Studies suggest that patients who undergo comprehensive genomic profiling for targeted treatment and clinical trial participation experience significantly improved clinical outcomes. This knowledge will inform strategies for cancer prevention, diagnostics, and treatment among service members.
This program will initially focus on enhancing cancer care support for SOF personnel with solid tumors. Following the initial phase, the program will be expanded to a broader population of armed forces, where Soteria’s approach empowers patients to access comprehensive genomic testing and advanced analytics, thereby providing advanced care options and support to care teams. The deidentified clinical reports generated from these tests will be shared with TGen for expert interpretation and summary analysis, providing an immediate benefit to patients by offering more precise and personalized care. In parallel, TGen scientists will conduct sequencing studies to better understand the molecular features and potential drivers of these cancers, thus providing insights that could positively impact the lives of SOF members for years to come. The partnership with TGen significantly enhances Soteria’s capabilities, by adding transformational research efforts in genomic-focused diagnosis, care, and monitoring. The initiative aims to improve service member patient navigation and document the efficacy of integrating precision medicine navigation.
“Advancements in modern precision medicine and advanced analytics allow us to provide transformational support to the protectors of our nation and way of life. Our agreements across this space – and most recently with TGen – mark a crucial step forward by providing better service to those who’ve served all of us,” said Soteria founder and CEO, Julia Civardi, biotechnology leader, cancer survivor and nationally recognized patient advocate who has dedicated her life’s work to helping patients and families.
“At TGen, we recognize the profound opportunity this project presents for our nation’s elite service members,” said TGen President and Research Director Jeffrey M. Trent, Ph.D. “We are committed to advancing precision medicine tailored to the unique challenges faced by SOF members and ensuring they receive the personalized care they deserve as they confront cancer.”
Additionally, insights gained from this initiative will guide the development of further support programs, including prevention and survivorship initiatives, to assist the military community throughout their cancer journeys.
Through this partnership, the overarching goal is to significantly enhance service members’ access to high-quality precision oncology tests and medical care, ensuring they receive the best possible high-touch engagement and support through their journey.
# # #
About Soteria Precision Medicine Foundation
Soteria Precision Medicine Foundation is a 501(c)3 non-profit organization dedicated to empowering patients, caregivers, and clinicians with the transformative capabilities of precision medicine navigation. Committed to breaking down barriers and informing cancer treatment planning, Soteria provides access to leading-edge technologies and personalized treatment options, making precision medicine available to all.
For more information about Soteria Precision Medicine Foundation, visit https://www.soteriaprecisionmedicine.org/
Media Contact:
Sierra Walters, sofsupport@soteriaone.com
About TGen, part of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is part of City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help patients through efficiency and effectiveness of the translational process. Follow TGen on Facebook, LinkedIn and X @TGen.
Media Contact:
Galen Perry, gperry@tgen.org